A Phase 1/2 Multi-Center Study Evaluating The Safety And Efficacy Of Impt-314, A Cd19/20 Bispecific Chimeric Antigen Receptor (Car) T Cell Therapy In Participants With Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Posted Date: Apr 26, 2024
- Investigator: Tahir Latif
- Specialties: Cancer, Lymphoma
- Type of Study: Drug
This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of IMPT-314, a bispecific chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive B-cell NHL. Three cohorts of participants will be enrolled: 1) CAR T naïve after at least two or more prior lines of treatment, 2) CAR T experienced and 3) refractory disease or relapse within one year of first line therapy.
Criteria:
Null
Keywords:
Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Car T
For More Information:
Emily Greve
NULL
cancer@uchealth.com